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Estrogen responsiveness of breast cancers can be associated with the presence or 
absence of the estrogen receptors (ER). Identification and analysis of estrogen 
responsive genes is important for proper diagnosis and treatment of estrogen receptor 
alpha (ERa) negative breast cancer. The objective of this study was to identify 
differentially expressed genes associated with estrogen treatment of ERa-negative MDA- 
MB-231 breast cancer cells and ERa-positive 231a breast cancer cells. Total RNA 
isolated from estrogen treated and untreated cells was subjected to differential microarray 
examination using the Affymetrix U133A human GeneChip, which consisted of 
approximately 22,500 genes. Data analyses were performed by Microarray Suite (MAS) 
5.0 and GeneSpring 6.0 software analysis systems. Over 10,000 genes and express 
sequence tags (ESTs) were differentially expressed in estrogen treated cells compared to 
nontreated cells. There were 529 genes with a 2-fold or higher increase in expression in 
estrogen treated MDA-MB-231 samples and 231 genes with a 2-fold or higher increase in 
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expression in estrogen treated 231a samples. Genes up-regulated in estrogen treated 
cells included BRCA1-associated protein 2 (BRAP2), ataxia telangiectasia mutated-Rad3 
related (ATR), vascular endothelial growth factor (VEGF) and several ESTs. This study 
demonstrated that estrogen treatment altered the expression of a diverse group of genes in 
ERa-negative breast cancer cells, thereby indicating that those genes are activated 
through mechanisms independent of ERa. The estrogen responsiveness of ERa-negative 
cells has implications for improved therapeutics of all types of breast cancers. 
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Breast cancer is one of the most common forms of cancer among women in the 
United States. It has been estimated that approximately 12.6 percent of American women 
will develop breast cancer during their lifetime. The onset of breast cancer is associated 
with the overexpression, and/or amplification of a number of genes including the ones 
encoding growth factors and growth factor receptors (Chrysogelos, S.A. et al. 1994). In 
the African-American population breast cancer appears to be aggressive, hormonally 
non-responsive and generally estrogen receptor alpha (ERa) negative (Elmore, J. et al. 
1998; Joslyn, S.A. and West, M.M. 2000). Due to such observations, it is evident that 
significant disparities in mortality rates exist between African-American and Caucasian 
patients with breast cancer. The reason for such disparities is attributed to biological 
differences between the races (Elmore, J. et al. 1998). However, some social scientists 
suggest that the differences in socioeconomic status, limited access to health care, and 
differences in cancer treatment contribute to the disparities in survival among African- 
American women (Greenwald, H. et al. 1996; Simon, M. et al. 1997; Heck K. et al. 
1997). Considering this disparity between African-American women and women in other 
populations with regard to ERa status, determining differential gene regulation due to 
estrogen could provide for more effective diagnosis and treatments. 
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In order to study the hormonal and molecular controls of growth and death in 
breast cancer cells, an expression profile of estrogen responsive genes in breast cancer 
should be established. The development of an expression profile is necessary because it 
can provide the opportunity to selectively target genes for disease intervention by 
appropriate drug development and gene therapies (Martin, K. et al. 2000). Previous 
studies have utilized DNA microarray analyses to identify differences in gene expression 
between estrogen treated and untreated ER-positive breast cancer cells, but there is little 
known literature pertaining to estrogen treated ER-negative breast cancer cells using 
global gene expression analysis. This study sought to determine the genetic profiles of 
breast cancer cells with regard to ER status. 
1.1 Objective 
This study attempted to determine non-ERa responses by: 
a) Establishing gene expression profiles of ERa negative breast cancer 
cells following estrogen treatment. 
b) Establishing gene expression profiles of ERa positive breast cancer 
cells following estrogen treatment. 
c) Studying the expression of estrogen responsive genes in ERa- 
negative/positive breast cancer cell lines. 
The goals of this study were to determine possible ER(3 and non-ERa gene targets 
in ERa negative breast cancer cells, and ultimately provide further insight into the 
development of improved therapeutics for treating breast cancer of all etiologies. 
CHAPTER 2 
LITERATURE REVIEW 
2.1 Breast Cancer 
The breasts are composed of fatty, connective, and lymphatic tissue. There are 
lobules, which make up the mammary glands for milk production during late pregnancy 
and after childbirth. The lobules are arranged around ducts that transport milk to the 
nipples for nursing. 
Breast cancer is a malignant tumor that results from uncontrolled cell growth in 
breast tissue. These cancerous cells replicate rapidly and may eventually spread to other 
parts of the body in a process known as metastasis. The most common types of breast 
cancer include ductal carcinoma in situ (DCIS), infiltrating ductal carcinoma (IDC), 
infiltrating lobular carcinoma (ILC) and lobula carcinoma in situ (LCIS). DCIS is 
noninvasive and curable in nearly all women. LCIS is not a “true” cancer but increases a 
woman’s risk of developing cancer in the future. IDC and ILC are invasive tumors that 
invade the surrounding fatty tissue of the breast and can spread to other parts of the body. 
Excluding cancers of the skin, breast cancer is the second most commonly 
diagnosed cancer among women. It is also the second leading cause of deaths due to 
cancer. It was estimated that 211,300 women in the United States would be diagnosed 
and 39,800 deaths would occur from breast cancer in 2003 (American Cancer Society). 
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Currently, there are over 2 million women living in the United States who have been 
treated for breast cancer. 
The aggressive behavior that is displayed in breast tumors of African-American 
women is characterized by an increase in necrosis as well as tumors that are larger in size 
(Elmore, J. et al. 1998). Tumors from African-American patients have been reported to 
have a higher rate of estrogen receptor negativity, in addition to tumors that are more 
likely to have inflammatory, medullary and papillary histology (Joslyn, S. 2002). 
Investigations have taken place in order to gain insight into the factors that may be 
responsible for the aggressive tumors found in African-American women. A study of the 
estrogen receptors in tumors derived from African-American women indicated there were 
alterations in the ERa mRNA (Koduri, S. et al. 2000). Poola et al. (2002) presented data 
that illustrated that functionally active ER isoform profiles in breast tumors of African- 
American women were different from those in Caucasian women. Specifically, the 
tumors in African-American women were characterized by decreased levels of the 
protective ER(3 isoform and elevated levels of the constitutively active ERa exon 5- 
deleted isoform. 
It is not known exactly what causes breast cancer, but there are certain risk factors 
that are known to be linked to the disease. A number of factors, such as age, family 
history, a woman’s age at birth of first child, early menarche and late menopause, are not 
modifiable. Alcohol consumption, use of postmenopausal hormones and obesity after 
menopause are other factors that are modifiable. Besides being female, age is a woman’s 
single most important risk factor for developing breast cancer (Henderson, I.C. et al. 
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1995; American Cancer Society 2001). Currently, about 8 out of 10 breast cancers are 
found in women over age 50 (American Cancer Society 2003). Breast cancers that result 
from inherited mutations in breast cancer susceptibility genes, such as BRCA1 and 
BRCA2, account for approximately 5-10 percent of all cases (Hyde, J. et al. 1992; Burke, 
W. et al. 1997). At this time, there is no known strategy to eliminate all risk of breast 
cancer; however, a woman’s best strategy is to minimize her known risk factors 
whenever possible. 
When a person has been diagnosed with breast cancer, choosing the best form of 
treatment or management of the disease is important. After an examination of the 
medical circumstances and the patient’s preferences, treatment may involve surgery, 
radiation therapy, chemotherapy, or hormone therapy (American Cancer Society 2003). 
Oftentimes, two or more of these methods are used in combination to effectively treat the 
disease. 
2.2 Estrogen and Estrogen Receptors 
There are many estrogens and estrogen-like molecules. 17(3-estradiol is a steroid 
derived from the conversion of androgen in the gonads, brain and adipose tissue through 
the P-450 superfamily member, aromatase. Androstenedione and testosterone are the 
obligatory precursors of estrogens. The P450 aromatase monooxygenase enzyme 
complex catalyzes the conversion of androstenedione and testosterone into estrogens 
(Gruber, C. et al. 2002). Estrogen plays an essential role in the development of various 
tissues and in the maintenance of numerous physiological processes (Charpentier, A. et 
al. 2000). In paradox, it has been well documented that estrogen has a critical role in the 
6 
etiology and progression of human breast and gynecological cancers (Henderson, B. et al. 
1982; Bernstein, L. et al. 1993; Pike, M. et al. 1993; McGonigle, K. et al. 1994; 
Adlercreutz, H. et al. 1994; Toniolo, P. et al. 1995). 
Estrogen action is mediated through estrogen’s ability to bind to the estrogen 
receptors (ER), a and (3. The estrogen receptors are ligand-activated transcription factors 
that are members of the steroid receptor superfamily. In short, estrogens bind to the ER 
in a target tissue; the ER is then activated by changes in the three-dimensional shape of 
the estrogen-ER complex. This complex dimerizes and binds to specific sites in the 
promoter region of estrogen-responsive genes. Transcription of target genes is initiated 
by coactivators and other regulatory proteins that bind to the external surface of the 
immobilized ER complex (Jensen, E. et al. 1962; Gorski, J. et al. 1968; Jensen, E. et al. 
1982; Kuiper, G. et al. 1996; Mosselman, S. et al. 1996; Bentrem, D. et al. 2003). The 
transcription complex either binds directly to DNA at an estrogen responsive element 
(ERE) or is tethered independently at AP-1 or SP-1 sites (Steinmetz, A. et al. 2001; 
Nilsson, S. et al. 2001 ; Bentrem, D. et al. 2003). Figure 1 represents the classic estrogen 
receptor signaling pathway. A new role of estrogens as mediators of rapid non-genomic 
effects has recently been identified, in addition to the classical genomic regulation of 
target gene expression. These rapid effects include the stimulation of nitric oxide release 
in vascular cells and the activation of Ras and Raf-1 kinase, resulting in the activation of 
ERK1/2 and the phosphorylation of transcription factors in both non-myocytes and 
cardiac myocytes (Chen, Z. et al. 1999; Kim, H. et al. 1999; Pratt, M. et al. 1998; Endoh, 
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H. et al. 1997; Russell, K. et al. 2000; Singer, C. et al. 1999; Watters, J. et al. 1997; 
Improta-Brears, T. et al. 1999; Nuedling, S. et al. 2000; de Sager, T. et al. 2001). These 
non-nuclear estrogen signaling events are thought to be mediated by ERs at the cell 
surface/plasma membrane (Ramirez, V and Zheng, J. 1996; Wade, C. et al. 2001 ; Santen, 





Figure 1. Estrogen signaling pathway. Estrogen (E2) binds to the estrogen receptors a 
or p. The estrogen-estrogen receptor complex can form as heterodimers or homodimers 
with the estrogen receptors. The complex then binds to DNA at estrogen responsive 
elements, initiating transcription. 
The identification of a second ER added a new dimension to the complexity of 
estrogen signaling. ERp was identified in Gustafusson’s laboratory in 1996 (Kuiper, G. 
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et al. 1996). Since the initial identification, five ERp isoforms have been cloned and 
characterized (Tong, D. et al. 2002). ERp has a structure and function similar to ERa, 
but its prognostic factors remain to be well established in breast carcinoma (Iwao, K. et 
al. 2000). ERp has been shown to bind to estrogen with an affinity resembling that of 
ERa and activates expression of receptor genes containing estrogen response elements in 
an estrogen-dependent manner (Pace, P. et al. 1997; Dotzlaw, H. et al. 1996). Although 
ERp has significant levels of expression in the central nervous system, cardiovascular 
and immune systems, urogenital tract, bone, kidney and lung, it is also expressed in 
breast cancer and is regulated by estradiol (Gustafusson, J. 2000; Vladusic, E. et al. 
2000). 
Recent studies indicated that the loss of ERp expression could be one of the 
events leading to the development of breast cancer, due to it regulating proliferation and 
invasion of breast cancer cells (Lazennec, G. et al. 2001). Most breast tumors tend to 
express ERa, but it has been seen in combination with ERp (Speirs, V. et al. 1999a; 
Jarvinen, T. et al. 2000). Dimerization of ERp and ERa indicate that the DNA binding 
domain of ERa is sufficient to dimerize with ERp (Pace, P. et al. 1997). The mere 
existence of ERp and its dimerization with ERa add greater levels of complexity to 
transcription and activation in response to estrogens. The coexpression of the two ER 
subtypes is associated with tumors with a poor prognosis, which may explain the failure 
of antiestrogen therapy in some breast cancer patients (Speirs, V. et al. 1999b). 
ERa and ERp also share homology in their central DNA-binding and carboxyl- 
terminal ligand binding domains, but there is very little similarity between the two 
9 
subtypes in the amino-terminal domain (Delaunay, F. et al. 2000). It is suggested that the 
amino-terminal region plays an important role in the control of the transcriptional activity 
exhibited by ERa and ERp (Paige, L. et al. 1999). The transcriptional activity of ERa 
has two different transcription activation functions (AF), AF-1 and AF-2, located in the 
amino-terminal region and in the carboxyl-terminal region of the ligand-binding domain, 
respectively (Tora, L. et al. 1989; Barkhem, T. et al. 1998). The function of the AF-1 site 
is hormone-independent, while the AF-2 site requires the presence of hormone for 
activation (Tora, L. et al. 1989). Even though ERp shares this similarity, the amino¬ 
terminal domain of ERP is 80 amino acids shorter and illustrates no sequence homology 
with that of ERa (Delaunay, F. et al. 2000; Ogawa, S. et al 1998). To date it is known 
that ERa and ERp have distinct cellular distributions, regulate separate sets of genes and 
can oppose each other’s actions on some genes. It is also known that ERP is widely 
expressed in both normal and malignant breast tissue and that there are proliferating cells 
in the breast which express ERp. However, it is still unclear whether ERp could serve as 
a good prognostic indicator, along with or independent of ERa, of breast cancer 
development. 
Estrogen is also known to contribute to the development and progression of breast 
cancer due to prolonged stimulation of breast ductal epithelium (Osborne, C. et al. 2000). 
The mitogenic effect of estrogen that results due to its interaction with ER allows for 
treatment regimens that include antiestrogens, synthetic compounds which oppose the 
actions of estrogens (Gottardis, M. et al. 1988; Sunderland, M. et al. 1991). This type of 
treatment is known as honnonal therapy; it uses hormones to prevent the growth, 
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spread or recurrence of breast cancer. Research has indicated that hormonal therapy can 
extend the lifespan of a person diagnosed with breast cancer with cancer cells that depend 
on hormones for proliferation. One of the most common drugs used for hormonal 
therapy is tamoxifen. Tamoxifen is used to treat patients with advanced stage breast 
cancer as well as patients with early stage breast cancer. Use of tamoxifen is determined 
by the patient’s ER status. Two-thirds of all breast cancer patients with ER-positive 
tumors will benefit from tamoxifen treatment, but most patients will eventually relapse 
(Speirs, V. et al. 199b). The tamoxifen resistant development is thought to occur due to 
an increased expression of ERp (Garcia, M. et al. 1992). Further research is needed to 
develop synthetic estrogen modulators that will combat breast tumors that are ERa- 
negative and ERa-positive. 
2.3 Microarray Technology 
With the human genome sequencing project as well as the advent of microarray 
technology, it is now possible to investigate the complexities of ER-mediated gene 
transcription on a more global scale, rather than one estrogen-responsive target gene at a 
time. DNA microarrays are used to simultaneously measure the expression levels of 
thousands of genes. New approaches based on microarray technology have been used to 
characterize distinctive gene expression patterns in human mammary epithelial cells and 
breast cancer (Pérou, C. et al. 1999; Soûlez, M. and Parker, M. 2001). This approach has 
also been used to monitor gene expression during breast cancer progression and to 
characterize breast tumors (Sgroi, D. et al. 1999; Nacht, M. et al. 1999; Bertucci, F. et al. 
2000; Pérou, C. et al. 2000; Soûlez, M. and Parker, M. 2001). 
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The effects of estradiol on increased proliferation and tumorigenesis in breast 
cancer cells have been well documented, and several recent studies using microarray 
techniques have begun to document the gene expression profiles in breast cancer. The 
focus of most of these studies has been on identifying genes overexpressed in breast 
cancer, patterns of gene expression associated with clinical outcome or prognosis, 
responses to chemotherapy or drug resistance, tumor aggressiveness, and classification of 
primary tumors (Jiang, Y. et al. 2002; van de Vijver, M. et al. 2002; van’t Veer, L. et al. 
2002; Sotiriou, C. et al. 2002; Zajchowski, D. et al. 2001; Pérou, C. et al. 2000; Sorlie, T. 
et al. 2001; Hedenfalk, I. et al. 2002). The role of ER expression has also been addressed 
in several studies in which distinct gene expression patterns associated with ER status 
have been identified (West, M. et al. 2001; Dressman, M. et al. 2001; Gruvberger, S. et 
al. 2001 ; Frasor, J. et al. 2003). Even with these recent studies, the exact role of 
estrogen-mediated gene regulation in ER-positive as well as ER-negative breast cancer 
and the manner by which these changes in gene expression affect breast cancer 
proliferation and progression is still unclear. Few microarray investigations have 
examined the role of estrogens in the regulation of gene expression, and the studies that 
have been done in breast cancer cells have been on a relatively limited scale, with few 
genes examined over a limited time course of hormone treatment (Soûlez, M. and Parker, 
M. 2001; Omoto, Y. and Hayashi, S. 2002; Levenson, A. et al. 2002; Inoue, A. et al. 
2002; Lobenhofer, E. et al. 2002). 
Current investigations by Frasor et al. (2003) have highlighted the diverse gene 
networks and metabolic and cell regulatory pathways through which estradiol operates to 
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achieve its widespread effects on breast cancer cells. Cunliffe et al. (2003) performed 
comparative analysis using gene expression patterns from in vitro and in vivo studies 
which revealed a significant association between specific gene clusters and differentiation 
in hormone receptor status and disease progression in tumor samples. Though these 
findings are very significant, they neglect to address or expound on gene profiles 
representing ER-negative breast cancer. 
Genes associated with ER-negative status are of particular interest because they 
may reveal the biological causes of the distinct behavior of these tumors (Pusztai, L. et al. 
2003). ER-negative tumors usually develop more often in premenopausal women, may 
recur sooner, and may spread more commonly to the lung, liver and the central nervous 
system (Clark, M. et al. 1996). Therefore, establishing and elucidating the mechanisms 
that cause regulation of ER-negative genes could provide potential targets for drug 
development. 
The question still remains how estrogen activation is mediated through ERp or 
non-genomic mechanisms in ERa-negative breast cancer cells. Therefore, it is important 
to study the effects of estrogen on gene expression in cells that are ERa-negative. The 
main objective of this research was to determine genetic profdes of breast cancer cells 
with regard to ER status. Expression profdes were established for ERa-negative and 
positive breast cancers following estrogen treatment. Estrogen responsive genes were 
identified and analyzed by Microarray Suite (MAS) 5.0 (Affymetrix, Santa Clara, CA) 
and GeneSpring 6.0 software (Silicon Genetics, Redwood City, CA). Results were 
confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). 
CHAPTER 3 
MATERIALS AND METHODS 
3.1 Cell Culture 
Human breast cancer cell lines, MDA-MB-231 and MCF-7, were obtained from 
the American Type Culture Collection (ATCC, Rockville, MD). The stable transfectants 
used in this study were constructed from the ERa-negative MDA-MB-231 cells and will 
be described later. All cell lines were maintained in RPMI 1640 medium (Sigma, St. 
Louis, MO) supplemented with 10% newborn calf serum, 10,000 U/ml penicillin and 10 
mg streptomycin, fungizone and 5 mg/ml gentamycin sulfate and incubated at 37°C in 
5% CO2. Prior to estrogen exposure, confluent cells were cultured for 24 hours in 
phenol-red free RPMI 1640 medium containing 10% charcoal stripped newborn calf 
serum supplemented with the previously mentioned antibiotics. 
3.2 Plasmids and Transformations 
The full-length human estrogen receptor-alpha (hERa) cDNA was provided in a 
pcDNA3 expression vector (pcDNA3hERa) as a generous gift from Dr. Kenneth Korach 
(NIEHS, National Institutes of Health, Bethesda, MD). In addition, pcDNA3 expression 
vector was purchased from Invitrogen (Carlsbad, CA) to use as a negative control for 
pcDNA3hERa. Transformations were performed by electroporation (Electro Cell 
Manipulator®, ECM 600, BTX, San Diego, CA) using XL-1 Blue and JM109 
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electrocompetent cells (Stragene, La Jolla, CA and Promega, Madison, WI), respectively. 
The vectors were diluted 1:10 and 1 pi was added to 400 pi of cells, then incubated on 
ice for 10 minutes. The DNA-cells mixtures were pulsed according to the electroporation 
conditions listed below. 
Charging Voltage: S 150V 
Nine hundred sixty microliters of Luria Broth (LB, Miler’s Modification, Sigma, St. 
Louis, MO) was added immediately after pulse and then transferred to microcentrifuge 
tubes for incubation at 37°C for 30 minutes with agitation. The cells were then 
centrifuged at 2,000 rpm for 30 minutes. Media were removed and the pellet, though not 
visible, was resuspended in 200 pi of LB and spread on LB agar plates containing 100- 
150 pg/ml of ampicillin. The plates were incubated at 37°C overnight. Several colonies 
from the LB agar plates were grown in 250 ml of Terrific Broth (TB; tryptone, yeast 
extract, K2HPO4, KTLPO4) containing 150 pg/ml of ampicillin and incubated in a shaker 
at 180-200 rpm at 37°C overnight. 
3.2.1 Plasmid DNA Isolation 
The transformed bacteria cells were harvested by centrifugation at 6,000 rpm for 
15 minutes. The supernatant was discarded and the pellet was placed on ice. Each 
Mode: T High Voltage/Resistance 
Capacitance: C 50pF 
Resistance: R R4 (72ohms) 
plasmid was isolated and purified utilizing the QIAGEN Plasmid Maxi Prep System 
(Valencia, CA). The QIAGEN plasmid purification system involves treating the cells 
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with an alkaline cell lysis buffer to break open the cells followed by filtration on an 
anion-exchange filter. This anion-exchange filtration system contained resin, a positively 
charged molecule, that bound strongly to negatively charged double-stranded plasmid 
DNA while other weakly bound impurities, such as RNA and proteins, were washed 
away leaving pure DNA. The DNA concentrations were determined by absorbance at 
260/280 nm ultraviolet light using a Beckman DU 650 spectrophotometer. 
3.2.2 Restriction Enzyme Digestion 
Restriction enzymes or endonucleases are bacterial enzymes that cleave both 
DNA strands at specific 4- to 8-bp nucleic acid sequences called restriction sites. The 
enzyme used in the digestion of pcDNA3hERa construct was EcoRI (Promega, Madison, 
WI). EcoRI enzyme is isolated from Escherichia coli and generates fragments with 
single-stranded regions or “sticky ends.” The restriction enzyme digestion reaction was 
composed of 0.5-1 pg of plasmid DNA, 10X restriction enzyme buffer (Multi-core 
buffer; 25 mM Tris Acetate, pH 7.5, 100 mM potassium acetate, 10 mM Mg Acetate, 1 
mM DTT), EcoRI (10 U/ml) and distilled, deionized water. The reaction was incubated 
in a 37°C water bath overnight. A 1% agarose (Fisher Scientific, Pittsburg, PA) gel made 
with IX Tris Borate EDTA (TBE; tris base, boric acid, EDTA, dH20) buffer was used in 
the electrophoresis of the restriction enzyme digestion. 
3.2.3 Sequence Analysis 
In addition to restriction enzyme analysis, sequence analysis was performed to 
verify the positive clone. The sequence analysis was performed utilizing the ABI Prism 
Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, 
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CA). This kit utilized the deoxynucleotide sequencing method in which modified DNA 
bases were incorporated into the DNA strand to terminate the extension of the strand by 
DNA polymerase. The dideoxynucleotides were labeled by the manufacturer with 
fluorescent dyes, and, through a series of reactions, the different terminator dyes 
fluorescences were read by the ABI Prism 377 DNA Sequencer. The sequencing reaction 
included: 200-500 ng of DNA, 0.5 pg primer (ERa 368 or 710) and 8 pi of the 
Terminator Ready Reaction Mix in a final volume of 20 pi. The Terminator Ready 
Reaction Mix contained dideoxynucleotides with the 6-carboxyfluorescein (6-FAM) 
linked to a dichlororhodamine (dRhodamine) dye and AmpliTaq DNA Polymerase, FS, a 
derivative of Thermus Aquaticus DNA that was modified to increase peak intensity of 
fluorescence. 
The sequencing reaction was performed in a DNA thermal cycler, GeneAmp PCR 
System 2400 (Perkin Elmer, Foster City, CA) under the following PCR conditions; 96°C 
for 30 seconds followed by 25 cycles of denaturing at 96°C for 10 seconds, annealing at 
50°C for 10 seconds, extension at 60°C for 4 minutes. The reaction was analyzed on an 
ABI Prism 377 Sequencer at the Molecular Biology Research Laboratory (MBRL) at 
Clark Atlanta University. Verification of the sequence was done by comparing with 
known sequences in the National Center of Biotechnology Information (NCBI) of the 
National Library of Medicine (NLM) database using the Basic Local Alignment Search 
Tool (BLAST). 
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3.2.4 Stable Transfection of ERa 
The MDA-MB-231 breast cancer cell line was stably transfected with the ERa 
expression plasmid (pcDNA3hERa) and the control plasmid (pcDNA3) by 
electroporation (Electro Cell Manipulator®, ECM 600, BTX, San Diego, CA). Cells 
(9.1xl05 cells/ml) were centrifuged at 1,000 rpm for 10 minutes to pellet and the pellet 
was resuspended in 10 ml of HeBS (20 mM Hepes, 137 mM NaCl, 5 mM KC1, 0.7 mM 
Na2HP04, 6 mM dextrose). Four hundred microliters of cells and 20 pg of DNA were 
added to a BTX disposable cuvette with a 2 mm chamber gap (BTX/Gentronics, San 





T 500 V Capacitance & Resistance Low Voltage 
C 1000 mF 
R R4 (72 ohms) 
Changing Voltage: S 150 V 
After pulse, cells were incubated at room temperature for 5 minutes, and then transferred 
to a cell culture dish containing fresh growth media. The cells were grown for 48-72 
hours before selection media containing 400 pg/ml Geneticin® (G-418 Sulfate, 
Invitrogen, Carlsbad, CA) was added. Geneticin® is an aminoglycoside selective agent 
related to gentamycin that blocks protein synthesis in mammalian cells by interfering 
with ribosomal function. Cells require the expression of the neomycin 
phosphotransferase gene that confers resistance to the antibiotic, Geneticin®. The stable 
transfectants continued to grow in selective media for 5 days. Selection continued for 5 
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more days in 600 pg/ml of Geneticin®. The remaining cell colonies were transferred 
using plastic cloning rings to 96-well plates (Fisher, Suwanee, GA) in the presence of 
non-selective media and grown until 90-100% confluency. This process continued until 
cell density was optimal for maintenance in tissue culture flasks. 
3.3 Treatment of Cells with Estrogen 
Seventeen (17) (3-estradiol (E2) was purchased from Sigma Chemical Co. (St. 
Louis, MO). A stock solution of E2 was made in ethanol at 20 mg/ml and was stored at 
2-8°C. A working concentration of lxlO'9 M was made directly in the tissue culture 
medium before treatment. 
Cells were seeded in 150 mm cell culture dishes (Coming, Fisher, Suwanee, GA) 
in sets of 2 or 3 dishes per cell line for each treatment. When cells became 90-100% 
confluent, phenol-red free RPMI 1640 media containing 10% charcoal stripped newborn 
calf serum supplemented with the previously described antibiotics were added for 24 
hours. The cells were rinsed twice with PBS, and fresh phenol-red free media was added 
containing lxl0‘9 M of E2. The estrogen remained on the cells for 2 and 12 hours with 
the respective untreated controls. These time points were used to identify early and 
intermediate/late expressed genes that have not been identified as estrogen regulated 
genes. 
3.4 Isolation of Total RN A 
Total RNA was isolated from the cell lines using TRIZOL Reagent (Invitrogen, 
Carlsbad, CA) or QIAGEN RNeasy Kit (Valencia, CA). The TRIZOL reagent is a 
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monophasic solution of phenol and guanidine isothiocyanate. During sample lysis, the 
reagent maintains the integrity of the RNA, while disrupting cells and dissolving cell 
components. The addition of chloroform is needed for purification and phase separation 
of the solution. 
The RNeasy principle combines the selective binding properties of a silica-gel- 
based membrane with the speed of spin technology. A specialized high-salt buffer 
system allows up to 1 mg of RNA longer than 200 bases to absorb to the RNeasy silica- 
gel membrane. In short, samples are lysed and homogenized in the presence of a highly 
denaturing buffer containing guanidine isothiocyanate, which immediately inactivates 
RNases to ensure isolation of intact RNA. Ethanol is added to provide appropriate 
binding conditions, and the sample is added to the column where total RNA binds and 
contaminants are efficiently washed away. High-quality RNA is eluted in RNase-free 
water and ready for use. 
After RNA isolation was completed, samples were resolved by electrophoresis on 
a 1 % agarose gel to determine stability. Concentrations were determined by 
spectrophotometry at absorbance 260/280 nm. 
3.5 Isolation of DNA 
The tissue culture cells were rinsed with IX PBS twice. Excess liquid was 
aspirated off the plate and 1 ml/108 cells of DNA digestion buffer (100 mM NaCl, 10 
mM Tris-Cl, pH 8, 25 mM EDTA, pH 8, 0.5% Triton-X 100 or 0.5% SDS, 0.1 mg/ml 
proteinase K) was added. The cells were scraped into tubes appropriate for the volume 
and samples were incubated in a 50°C water bath for lhr to overnight. A 
20 
phenol/chlorofonn extraction was performed by adding an equal volume of phenol 
saturated with Tris-Cl (pH 8.0) to the samples. The samples were mixed gently by 
inversion and centrifuged for 15-30 minutes at room temperature. The supernatant was 
transferred to another tube and an equal volume of chloroform was added. The samples 
were mixed by inversion and the phases were separated as previously described. DNA 
was precipitated by the addition of 0.6 volumes of 3 M sodium acetate and 2 volumes of 
100% ethanol at -20°C for 30 minutes. After centrifugation, the pellet was air-dried for 
5-10 minutes and resuspended in the appropriate volume of dH20. Concentrations were 
determined by UV spectrophotometry at absorbance 260 nm. 
3.6 GeneChip Microarrays 
The HG-U133A Array was used to measure the expression levels of a vast 
majority of genes. This array is a part of the HG-U133 set from Affymetrix, Inc. (Santa 
Clara, CA) that includes approximately 22,500 human genes. The total RNA was 
shipped to Medical College of Georgia (Augusta, GA) for processing. RNA was 
converted to cRNA and hybridized to the HG-U133A GeneChip according to standard 
Affymetrix protocol. Briefly, RNA was first converted to double-stranded cDNA using 
an oligo-dT primer with a T7 RNA polymerase site on the 5’ end. It was then used 
directly in an in vitro transcription reaction in the presence of biotinylated nucleotides 
following manufacturer protocol (Enzo Bioarray High Yield RNA Transcript Kit, 
Farmingdale, NY). Labeled antisense RNA was then fragmented to improve 
hybridization kinetics, and hybridized to the high-density microarray. The chips were 
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washed, stained with phycoerythrin-streptavidin, and scanned according to the 
manufacturer instructions. 
Initial analysis was performed using Microarray Suite 5.0 (MAS) software 
(Affymetrix). Average intensities for each GeneChip were globally scaled to a target 
intensity of 150. For each transcript, MAS 5.0 applied one-sided Wilcoxon signed rank 
test to each probe set on the experimental (2hr and 12hr) chip and compared it to its 
corresponding probe set on the baseline (control) chip. MAS 5.0 determined those 
transcripts that were differentially expressed based on user-defined limits. Further 
analysis was performed using GeneSpring 6.0 software (Silicon Genetics, Redwood City, 
CA) to obtain fold-change and p-values for each gene at each time point relative to 
untreated control. 
Microarray data were generated from three independent microarray experiments 
performed for each timepoint per cell line. In order to aid in the selection of genes, 
specific criteria were generated. Fold induction was the first criterion; a cut-off of 2-fold 
increase or decrease was defined for selecting genes of interest. Only those genes that 
had similar expression levels in at least two independent experiments and showed at least 
a 2-fold increase or decrease in expression were selected as E2 regulated candidate genes 
for further analysis. The stringency was increased to 5-fold in order to select genes with 
the highest fold change. Secondly, genes were screened based on the raw intensity of 
each gene’s signal. When microarray chips were scanned, each transcript on the array 
emitted a signal and the intensity was measured. The cut-off intensity was 150 units. 
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Genes were then prioritized according to those that were unknown or had an inferred 
function, transcription factors, receptors, breast cancer related and enzymes. 
3.7 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Analysis 
RNA was reverse transcribed using Superscript II (Invitrogen, Carlsbad, CA) with 
random hexamer or oligo dT primers. Primers were designed using OLIGO® Primer 
Analysis Software version 4/5 (NBI, Plymouth, MN) for a select number of differentially 
expressed genes. Selection was based on the fold induction of genes identified by MAS 
5.0. A list of primers is shown in Table 1. The cDNA was amplified in a 20 pi reaction 
mixture. The PCR conditions were 95°C for 3 min followed by 35 cycles of denaturing 
at 95°C for 30 sec, annealing at 58°-60°C for 45 sec, extension at 72°C for 2 min and a 
final extension at 72°C for 5 min. PCR products were analyzed on 1-2% agarose gel and 
imaged on a BioRad ChemiDoc System (Hercules, CA). For breast tissue samples, RNA 
was isolated using RNeasy kit (Qiagen, Valencia, CA). Synthesis of cDNA was 
performed using GeneAmp RNA PCR kit (Perkin Elmer, Boston, MA) and amplified by 
PCR. 
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Table 1. List of PCR primers 
PCR PRIMERS 
ERa 368 5' -GGG GAG GGC AGG GGT GAA GTG 
ERa 710 5' -GGA GCG CCA GAC GAG ACC AAT CAT 
GAPDH (forward) 5' -ACA CAT GCC ATC ACT GCC 
GAPDH (reverse) 5' -GCC TGC TTC ACC ACC TTC TTG 
ERp (forward) 5' -TAG TGG TCC ATC GCC AGT TAT 
ERp (reverse) 5’ -GGG AGC CAC ACT TCA CCA T 
ERa (forward) 5' -AAT TCA GAT AAT CGA CGC CAG 
ERa (reverse) 5' -GTG TTT CAA CAT TCT CCC TCC TC 
NEO 634 5' -GTG TTC CGG TGT CAG CGC CA 
NEO 1169 5' -GTC CTG ATA GCG GTC CGC CA 
ESR2 466 5' -CAA CTG CAG TCA ATC CAT CTT ACC C 
ESR2 663 5' - AAG GAG AAA GGT GCC CAG GTG 
ERa 817 5’ -AAT TCA GAT AAT CGA CGC CAG GGT G 
ERa 1137 5' -GTG TTT CAA CAT TCT CCC TCC TCT T 
ATR 3722 5' -CTT GTC TGG GCT CCC TTC TCA GTC 
ATR 4170 5’ -CCC CCA ATT CCC CTA AAC ATT CC 
CHAPTER 4 
RESULTS 
4.1 Creation of Stable Transfectant Cell Lines 
Stable transfectant cell lines, MDA-MB-231hERa (231a) and MDA-MB- 
23 INeoô (Neo 6), were created by electroporation of MDA-MB-231 breast cancer cells 
with ERa and an empty pcDNA3 vector, respectively. Prior to transfection, ERa 
plasmid DNA was isolated from transformed E. coli cells and restricted with EcoRI 
(Figure 2). The digestion reaction confirmed the presence of the ERa cDNA in the 
pcDNA3 vector. Further verification was performed by sequence analysis. 
The pcDNA3 plasmid DNA isolated from transformed bacteria cells was analyzed 
by electrophoresis on a 0.7% agarose gel (Figure 3); therefore, confirming that the empty 
vector was incorporated. After a successful transfection and selection process, the cells 
were maintained in culture under normal conditions for several weeks prior to 
experimental use. A RT-PCR screening for the presence of the neomycin resistant gene 
(NEO) was performed to ensure the transfected cell line did contain the pcDNA3 
construct. The primers that were used for this experiment are shown in Table 1. The 
results from the RT-PCR screening with NEO specific primers are shown in Figure 4. 
The NEO primers produced a band at a size of 550 bp on a 2% agarose gel. Samples 
from the MDA-MB-231 and 231a cell lines were also used. The MDA-MB-231 sample 
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Lane 1 - 1 kb Marker 
Lane 2- ERa plasmid DNA 
Lane 3- ERa plasmid DNA cut w/ EcoRI 
Lane 4- ERp plasmid DNA 
Lane 5- ERP plasmid DNA cut w/ EcoRI 
Figure 2. EcoRI digestion of ERa plasmid DNA. Plasmid DNA was isolated and 
purified from transfonned E.coli cells. The DNA was utilized in a restriction digest 
reaction with EcoRI restriction enzyme to detect the presence of ERa cDNA in the 
vector. ERp plasmid DNA was used to compare the sizes of the cDNA. 
was negative for the NEO screening and the 231a sample was positive. Primers for the 
reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used to 
confirm the success of the RT reaction and to verify that approximately equal amounts of 
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cDNA template was added to eaeh reaction. GAPDH produced a band at an approximate 
size of 200 bp. The establishment of these cell lines facilitates the uniform analysis of 
ERcx activity in an environment that is endogenously naive of ERcx. 
2 3 
Lane 1- lkb Marker 
Lane 2 & 3- pcDNA3 plasmid DNA 
Figure 3. pcDNA3 plasmid DNA. Purified plasmid DNA was analyzed by 
electrophoresis to confirm the presence of the empty pcDNA3 vector in the transformed 




Lane 1 - 23 la 
Lane 2 - Neo 6 
Lane 3 - MDA-MB-231 
Lane 4 - MCF-7 
Figure 4. RT-PCR screening for neomycin (NEO) resistant gene. RT-PCR was used 
to detect the expression of NEO in the transfected cell lines, 231a and Neo 6. The 
neomycin resistant gene is incorporated into the vector for selection of stable transfectant 
cell lines. GAPDH was used as an internal control to verify approximately equal cDNA 
templates in all samples. 
4.2 ER Status of Breast Cancer Cell Lines 
Previous studies have identified MCF-7 breast cancer cells as ER positive and 
MDA-MB-231 breast cancer cells as ER negative. In order to confirm these findings in 
our batch of cell lines, RT-PCR analysis was performed using ERa and ERp primers. 
The stable transfectants, 231 a and Neo 6, were also screened for the presence and/or 
absence of ERa and ERp. Figure 5 shows the results from the RT-PCR screening for ER 
status. The ERa primers (817/1137) produced a band at a size of 320 bp on a 1.5% 
agarose gel in MCF-7 and 23 la breast cancer cells. The ERp primers (ESR2, 466/663) 
produced a band at a size of 197 bp on a 1.5% agarose gel in MDA-MB-23 1, Neo 6 and 
231 a cells. This set of ERp primers produced a faint band in MCF-7 cells during this 
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particular experiment, but a broader band has been produced in previous experiments and 
with other ERp primers. The faint expression of ERp seen in Neo 6 and 231a cells eould 
be the result of transfection. GAPDH produced a band at an approximate size of 200 bp 
in all sample. 




Lane 1 - MCF-7 
Lane 2 - MDA-MB-231 
Lane 3 - Neo 6 
Lane 4 - 231 a 
Figure 5. RT-PCR screening for ER status. Total RNA was extracted from each cell 
line and used in RT-PCR analysis to detect the presence of ERa and/or ERp. GAPDH 
was used as an internal control to confirm approximately equal cDNA templates in all 
samples. 
4.3 Effects of Estrogen on Cell Proliferation 
Figure 6 shows the growth data of MDA-MB-231 cells after treatment for 96 hrs 
with 17p-estradiol. During the first 48 hrs, the control and E2 treated cultures showed no 
differences in growth. There was a 5.8% and 22% difference in growth at 72 hrs and 96 
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hrs, respectively, between E2 and control (at 96 hrs, P= 0.04). As shown in Figure 7, E2 
and control treatment of 231 a cultures showed no change in the rate of growth from 0-48 
hrs. However, at 96 hrs, E2 stimulated growth 18.5% higher than control (P= 0.06). 
Figure 8 illustrates the effect of E2 treatment on proliferation of Neo 6 cells. Overall, the 
growth of the cells was inhibited in the presence of E2 and in the untreated control cells. 
This could be due to the mere presence of the empty vector in these cells or the use of 
charcoal stripped-serum growth medium. 




Figure 6. MDA-MB-231 growth curve. MDA-MB-231 cells (lxl05/ml) were treated 
with E2 and control untreated for 0-96 hrs. At 24 hr intervals, viable cells were 
determined using crystal violet blue stain. The growth curve is an average of three 
separate experiments performed in duplicate. 
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231a Growth Curve 
Control 
■ E2 
0 24 48 72 96 
TIME (HR) 
Figure 7. 231a growth curve. 23 la cells (lxl05/ml) were treated with E2 and control 
untreated for 0-96 hrs. At 24 h intervals, viable cells were determined using crystal 
violet blue stain. The growth curve is an average of three separate experiments 
performed in duplicate. 
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Neo 6 Growth Curve 
Figure 8. Neo 6 growth curve. Neo 6 cells (lxl05/ml) were treated with E2 and control 
untreated for 0-96 hrs. At 24 hr intervals, viable cells were determined using crystal 
violet blue stain. The growth curve is an average of three separate experiments 
performed in duplicate. 
4.4 Identification of Estrogen-Regulated Genes 
Analysis of microarray data using Affymetrix MAS 5.0 and GeneSpring 6.0 
identified over 11,000 genes and express sequence tags (ESTs) that were differentially 
expressed in 12 hr estrogen treated MDA-MB-231 cells in comparison with non-treated 
cells. There were 320 genes with a 2-fold or higher increase in expression. Twenty-four 
of those genes were induced approximately 5-fold or higher (Table 2). There were only 2 
genes that were down-regulated 2-fold or less. In 2 hr estrogen treated MDA-MB-231 
samples compared with control, there were more than 10,000 genes expressed. Included 
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in those genes were 209 genes with a 2-fold or higher increase in expression and 9 genes 
were down-regulated greater than 2-fold. There were 13 genes with a differential 
expression of 5-fold or higher increase in the 2 hr E2 treated MDA-MB-231 samples 
(Table 3). 
Table 2. Estrogen up-regulated genes at 12 hrs in MDA-MB-231. 
Fold 
Change Gene Name Description 
18.4 MPDU1 Mannose-P-dolichol utilization defect 1 
15.3 STIP1 Stress-induced-phosphoprotein 1 
12.1 PFAAP5 Phosphonoformate immuno-associated protein 5 
10.9 IL24 Interleukin 24, transcript variant 1 
10.6 MAGEA11 Melanoma antigen, family A, 11 
10.6 AKR1C2 Aldo-keto reductase family 1 member C2 
7.8 RGS4 Regulator of G-protein signaling 4 
7 NQOl NAD(P)H dehydrogenase, quinonel 
6.6 K1AA1026 Alpha 1, type 1 collagen preproprotein 
6.5 PRO0478 Chromosomal protein 
6.5 ILIA Interleukin 1-alpha 
6.4 PSMC3 
Protéasome (prosome, macropain) 26S subunit, ATPase 
3 
6.1 MEST 
Mesoderm specific transcript homolog, transcript 
variant 1 
5.8 SMA5 Spinal muscular atrophy 5 
5.8 EST: Hs.373565 
Transcribed sequence with moderate similarity to Flyp. 
Protein FLJ11267 
5.8 ANGPTL4 Angiopoietin-like 4, transcript variant 2 
5.8 C4BPB Complement component 4-binding protein 
5.7 NFYA Nuclear transcription Factor Y, alpha 
5.5 PCDH7 
BH-protocadherin (brain-heart), 
transcript variant a 
5.5 C6orfl 1 Chromosome 6 open reading frame 11 
5.5 BUB 1 Budding uninhibited by benzimidazoles 1 homolog 
5.5 BTF Bcl-2-associated transcription factor 
5.3 PQBP1 Polyglutamine binding protein 1 
5.1 DBT Dihydrolipoamide branched chain transacylase 
This table represents genes with a differential expression of >5-fold increase in MDA- 
MB-23 1 cells treated with E2 for 12 hr compared with untreated cells. 
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Table 3. Estrogen up-regulated genes at 2 hrs in MDA-MB-231. 
Fold Change Gene Name Description 
23.2 MPDU1 Mannose-P-dolichol utilization defect 1 
12.2 STIP1 Stress-induced-phosphoprotein 1 
7.8 RGS4 
Homo sapiens regulator of G-protein signaling 
4 
7.3 DDX9 DEAH box polypeptide 9 
7.2 NFYA Nuclear transcription Factor Y, alpha 
6.9 SPTBN1 Homo sapiens spectrin, beta, non-erythrocytic 1 
6.2 BTF Bcl-2-associated transcription factor 
6 DDX9 DEAH box polypeptide 9 
5.7 BUB 1 
Budding uninhibited by benzimidazoles 1 
homolog 
5.6 USP10 Ubiquitin specific protease 10 
5.3 MYOID EST:nq24b02.sl ; Myosin ID 
5.2 CTI Collagen type I 
5.1 SEC22L1 SEC22 vesicle trafficking protein-like 1 
This table represents genes with a differential expression of >5-fold increase in MDA- 
MB-23 1 cells treated with E2 for 2 hr compared with untreated cells. 
Evaluation of the 231 a E2 treated samples revealed that there were over 9,000 
genes expressed in 12 hr E2 treated sample compared to control. One hundred twenty- 
three (123) genes were up-regulated greater than 2-fold; 145 genes were down-regulated 
2-fold or more. There were 2 genes that met the 5-fold increase in gene expression cut¬ 
off in the 12 hr E2 treated sample compared to control (Table 4) and 5 genes were 
identified as down-regulated greater than 5-fold in this sample (Table 5). More than 
10,000 genes were regulated by E2 in 2 hr 23 la treated samples compared to the control. 
Of these, 108 genes were up-regulated greater than 2-fold and 7 genes were down- 
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regulated greater than 2-fold. There were 3 genes with 5-fold or greater increase in 
expression (Table 6), but no genes met the 5-fold decrease in gene expression cut-off in 
the 2 hr E2 treated 231a sample compared to control. 
Table 4. Estrogen up-regulated genes at 12 hrs in 231a. 
Fold Change Gene Name Description 
8.6 IL13RA2 
Homo sapiens interleukin 13 receptor, 
alpha 2 
5.5 ZNF492 Zinc finger protein 492 
This table represents genes with a differential expression of >5-fold increase in 23la 
cells treated with E2 for 12 hr compared with untreated cells. 
Table 5. Estrogen down-regulated genes at 12 hrs in 231a. 
Fold Change Gene Name Description 
-16.2 PHLDA1 Pleckstrin homology-like domain, family A, member 1 
-6.3 LSM4 U6 small nuclear RNA associated protein 4 
-5.9 FUS-CHOP Fusion protein 
-5.4 DRAP1 DR 1-associated protein 1 (negative cofactor 2 alpha) 
-5.2 PCIA1 Cross-immune reaction antigen PCIA1 
This table represents genes with a differential expression of >5-fold decrease in 23 la 
cells treated with E2 for 12 hr compared with untreated cells. 
Table 6. Estrogen up-regulated genes at 2 hrs in 231 a. 
Fold Change Gene Name Description 
10.9 IL13RA2 Interleukin 13 receptor, alpha 2 
8.2 TIMP3 Tissue inhibitor of metalloproteinase 3 
5.1 DDX9 DEAH box polypeptide 9 
This table represents genes with a differential expression of >5-fold increase in 231a 
cells treated with E2 for 2 hr compared with untreated cells. 
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Comparative analysis of the microarray data from 231a and MDA-MB-231 
samples produced lists of genes that were differentially expressed among the cell lines. 
In the untreated 231 a sample compared to the untreated MDA-MB-231 sample, there 
were over 10,000 genes that were differentially expressed. That included 26 genes that 
were up-regulated 2-fold or more and 234 genes that were down regulated 2-fold or 
more. The previously used fold change filter of 5-fold increase or decrease was applied 
to the data. This revealed 6 genes that were down-regulated 5-fold (Table 7), but there 
were not any up-regulated genes that met the filter. When data for the 2 hr E2 treated 
231a sample was compared to the 2hr E2 treated MDA-MB-231 samples it showed that 
there were over 11,000 genes differentially expressed. Among the vast number of genes, 
212 genes were identified as 2-fold up-regulated and 10 genes were identified as 2-fold 
down-regulated. Thirteen ( 13) genes met the 5-fold increase filter (Table 8), but no genes 
were down-regulated 5-fold. Over 9,500 genes were differentially expressed in the 12 hr 
E2 treated 231a sample compared to the 12 hr E2 treated MDA-MB-231 sample. One- 
hundred-twenty five (125) genes were up-regulated 2-fold, while there were 148 genes 
that were down-regulated 2-fold. The filter identified one (1 ) gene that was up-regulated 
(Table 9) and 5 genes that were down-regulated (Table 10). 
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Table 7. Genes down-regulated at 0 hr in 231 a. 
Fold 
Change Gene Name Description 
-11.4 SLC16A3 Solute carrier family 16 (monocarboxylic acid transporters) 
-8.7 LSM4 U6 snRNA-associated Sm-like protein 4 
-8.2 PHLDA1 Pleckstrin homology-like domain, family A, member 1 
-7.6 DRAP1 DR 1-associated protein 1 (negative cofactor 2 alpha) 
-5.2 H2AFY H2A histone family, member Y 
-5.1 LAMP 1 Lysosome-associated membrane glycoprotein 
This table represents genes with a differential expression of >5-fold decrease in 231a 
cells compared with MDA-MB-231 cells. 
Table 8. Estrogen up-regulated genes at 2 hrs in 231 a compared with MDA-MB-231. 
Fold 
Change Gene Name Description 
20.6 MPDU1 Mannose-P-dolichol utilization defect 1 
19.6 SI OOP SI00 calcium binding protein P 
12.7 STIP1 Stress-induced-phosphoprotein 1 
6.9 SPTBN1 Spectrin, beta, non-erythrocytic 1 
6 POLD4 Polymerase (DNA-directed), delta 4 
5.9 NFYA Nuclear transcription factor Y, alpha 
5.9 PGM5 Phosphoglucomutase 5 
5.7 TNP02 Transportin 2 (importin 3, karyopherin beta 2b) 
5.4 TXNIP Thioredoxin interacting protein 
5.1 NNMT Nicotinamide N-methyltransferase 
5.1 DDX9 DEAH box polypeptide 9 
5 TRIO Triple functional domain (PTPRF interacting) 
5 PXN Paxillin beta 
The genes in this table were up-regulated >5-fold in 2 hr E2 treated 231a cells compared 
with 2 hr E2 treated MDA-MB-231 cells. 
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Table 9. Estrogen up-regulated genes at 12 hrs in 231a compared with MDA-MB-231. 
Fold Change Gene Name Description 
5.5 ZNF492 Zinc finger protein 492 
This gene was up-regulated >5-fold in 12 hr E2 treated 231a cells compared with 12 hr 
E2 treated MDA-MB-231 cells. 
Table 10. Estrogen down-regulated genes at 12 hrs in 231a compared with 
MDA-MB-231. 
Fold Change Gene Name Description 
-16.2 PHLDA1 pleckstrin homology-like domain, family A. member 1 
-6.3 LSM4 U6 snRNA-associated Sm-like protein 4 
-5.9 FUS1 Fusion gene in myxoid liposarcoma 
-5.4 DRAP1 DR 1-associated protein 1 (negative cofactor 2 alpha) 
-5.2 PC1A1 Cross immune reaction antigen PCIA1 
This table represents genes with a differential expression of >5-fold decrease in 12 hr E2 
treated 231 a cells compared with 2 hr E2 treated MDA-MB-231 cells. 
Additional analysis using GeneSpring 6.0 (Silicon Genetics, Redwood City, CA) 
allowed for generating lists of selected genes and for visualizing data by different 
methods. The similarities and differences between gene expression profiles of two given 
samples can be visualized using scatterplots. In a scatterplot, each point represents the 
expression value of a gene in two experiments, one plotted on the X-axis (untreated 
control) and the other one on the Y-axis (E2-treated) (Figures 9-12). Genes with equal 
expression values lined up on the central diagonal line, whereas outliers correspond to 
up- or down-regulated genes. Although the vast majority of genes have transcript levels 
that remain unchanged, there were outliers in each experimental condition when cells 
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were treated with E2 at different time points. Most of the outliers were up-regulated 
genes in E2 treated cells compared with untreated control cells; with the exception being 
12 hr E2 treated 231 a cells which exhibit more down-regulated genes. This implies that 
the presence of ERa in an exogenous system causes the repression of select genes. 
Control (no E2) 
Figure 9. Scatterplot of 2 hr E2 treated MDA-MB-231. Expression profde of the 
control untreated (X-axis) and 2 hr E2 treated (Y-axis) MDA-MB-231 cells is shown as a 
bivariate scatterplot of genes from three microarray experiments. The averaged values 
are normalized adjusted intensities representing levels of expression (scale on each axis). 
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Control (no E2) 
Figure 10. Scatterplot of 12 hr E2 treated MDA-MB-231. Expression profile of the 
control untreated (X-axis) and 12 hr E2 treated (Y-axis) MDA-MB-231 cells is shown as 
a bivariate scatterplot of genes from three microarray experiments. The averaged values 
are normalized adjusted intensities representing levels of expression (scale on each axis). 
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Figure 11. Scatterplot of 2 hr E2 treated 231a. Expression profile of the control 
untreated (X-axis) and 2 hr E2 treated (Y-axis) 231 a cells are shown as a bivariate 
scatterplot of genes from three microarray experiments. The averaged values are 
normalized adjusted intensities representing levels of expression (scale on each axis). 
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Control (no E2) 
Figure 12. Scatterplot of 12 hr E2 treated 231a. Expression profile of the control 
untreated (X-axis) and 12 hr E2 treated (Y-axis) 231a cells are shown as a bivariate 
scatterplot of genes from three microarray experiments. The averaged values are 
normalized adjusted intensities representing levels of expression (scale on each axis). 
Venn diagrams were created to quickly visualize genes common to more than one 
sample, as well as those present only in a particular sample. The genes illustrated as 
numbers in the diagrams were extrapolated from three gene lists created for each sample. 
The three gene lists were subtracted from a pool of more than 22,000 genes in the HG- 
U133A genome; the number of genes that remain are highlighted in the gray background 
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above the “all genes” label. Figure 13 and 14 show the number of genes up-regulated 2- 
fold or higher in the MDA-MB-231 and 231 a cells at 2 and 12 hrs, and the number of 
genes expressed in the control cells (untreated at 0 hr). The genes represented in the 
diagrams are automatically distributed according to two parameters; time and treatment. 
In Figure 13, there are 23 genes highlighted in yellow that respond to E2 treatment only. 
This means the time or length of E2 treatment has no effect on their expression because 
they were up-regulated in both the 2 hr and 12 hr samples. The 182 genes highlighted in 
pink represent genes overexpressed at 12 hrs, but are not dependent on the E2 treatment 
because they are also a part of the untreated (0 hr) gene list. Highlighted in aqua blue, are 
128 genes overexpressed at 2 hrs, but not responsive to the E2 treatment because they are 
members of the untreated (0 hr) gene list. The number highlighted in white, 123, 
represent the genes that are not dependent on treatment or time because they are members 
of all three gene lists. The 80 genes highlighted in green represent genes that uniquely 
respond to the E2 treatment and time at 2 hrs because they are not seen in any other gene 
list. Likewise, the 142 genes highlighted in red represent genes that uniquely respond to 
the E2 treatment after 12 hrs only, because they are not part of any other gene list. 
Highlighted in dark blue are 10,887 genes that were not up-regulated by estrogen in (0 hr) 
MDA-MB-231 cells. In Figure 14, there are 3 genes highlighted in yellow that respond 
to E2 treatment only. This means the time or length of E2 treatment has no effect on 
their expression because they were up-regulated in both the 2 hr and 12 hr samples. The 
112 genes highlighted in pink represent genes overexpressed at 12 hrs, but are not 
dependent on the E2 treatment alone because they are also a part of the untreated (0 hr) 
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gene list. Highlighted in aqua blue, are 97 genes overexpressed at 2 hrs, but not 
dependent on the E2 treatment because they are members of the untreated (0 hr) gene list. 
The number highlighted in white, 11, represents the genes that are not responsive to 
treatment or time because they are members of all three gene lists. The 209 genes 
highlighted in green represent genes that uniquely respond to the E2 treatment and time at 
2 hrs because they are not seen in any other gene list. Likewise, the 42 genes highlighted 
in red represent genes that uniquely respond to the E2 treatment after 12 hrs, because they 
are not part of any other gene list. Highlighted in dark blue are 10,631 genes that are 
exclusive to the untreated (0 hr) 231a cells. The Venn diagrams illustrate that there are 
more genes up-regulated by E2 in MDA-MB-231 than in 231a. 
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M D A-MB-231(12h)>x2 MDA-MB-231 (2H)>x2 
MDA231 (Oh)ALL Genes 
Figure 13. MDA-MB-231 Venn diagram. A Venn diagram was created using genes 
with a differential expression of 2-fold or more up-regulated in MDA-MB-231 cells 




Figure 14. 231a Venn diagram. A Venn diagram was created using genes with a 
differential expression of 2-fold or more up-regulated in 231a cells treated with E2 for 2 
and 12 hrs and genes expressed in untreated (0 hr) 231a cells. 
Further analysis of up-regulated genes showed that there were genes significantly 
up-regulated in treated cells compared with untreated control cells, as well as genes not 
expressed in the control cells and up-regulated after treatment only. The major functional 
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categories for the genes (Figures 15 and 16) include apoptosis, cell adhesion, cell cycle, 
cytoskeleton, enzymes, growth factors/hormones, nucleotide processing, protein 
processing, receptors, signal transduction, transcription and transporters. Figures 15 and 
16 illustrate the number of genes up- and down-regulated by E2 at 2 and 12 hrs in MDA- 
MB-231 and 231a cells, respectively. As expected, a greater proportion of genes 
involved in signal transduction and transcription were regulated by E2. These include 
genes such as signal transducer and activator of transcription 6 (STAT6), insulin-like 
growth factor 2 receptor (IGF2R), transcription factor 7-like, T-cell specific (TCF7L1), 
TGF beta-induced factor 2 (TGIF2). It is evident that a greater proportion of genes is 
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Figure 15. Functional categories of genes regulated by E2 at 2 and 12 hrs in MDA- 
MB-231 cells. The solid yellow bar represents genes up-regulated by E2 and the solid 





Figure 16. Functional categories of genes regulated by E2 at 2 and 12 hrs in 231a 
cells. The solid yellow bar represents the genes up-regulated by E2 and the solid green 
bar represents the genes down-regulated by E2. 
4.5 E2 Regulation of ATR 
A number of genes associated with the cell cycle are known E2 regulated genes. 
An example of such are cyclin Dl, cyclin A2, cell division cycle 2 (CDC2) and cyclin- 
dependent kinase inhibitor 1A (Frasor, J. et al. 2003). Evaluation of the genes in the cell 
cycle category that was created in GeneSpring 6.0, revealed the presence of ATR, ataxia 
telangiectasia-related protein. Our preliminary data suggested that ATR, also known as 
FRP1 (FKBP12-rapamycin associated protein (FRAP)-related protein), was induced by 
E2 at 12 hrs in MDA-MB-231. In 2 of 3 independent microarray experiments, ATR was 
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up-regulated greater that 5-fold; therefore, the decision was made to analyze this gene 
further. 
Reverse transcriptase PCR was performed to validate the data. Figure 17 shows 
the regulation of ATR by E2. ATR primers produced a band at an approximate size of 
450 bp on a 2% agarose gel in samples of MDA-MB-231 (E2, 2 hrs and 12 hrs) and 
untreated, MCF-7 and 231 a. The relative intensity of the product was higher at 12 hrs 
and 2 hrs than in the untreated MDA-MB-231 cells, which was lower than the intensity 
produced in MCF-7 and 231a cells. Primers for GAPDH were also assayed as an 
internal control. ATR expression was also analyzed in normal (N) and tumor (T) breast 
tissues (Figure 18). The normal sample, 4N was the only breast tissue sample that did not 
express ATR. The other samples, which were tumors, displayed various intensities of 
ATR expression (Figure 18A). These results suggest that ATR plays a role in breast 
cancer development, but there were not enough normal and tumor breast tissue samples 
examined to support this claim. We gained access to additional normal and tumor breast 
tissue samples and screened them for ATR expression (Figure 18B). There were 5 of 6 
normal tissues that expressed ATR, while only 3 of 7 tumor tissues expressed ATR. This 
implies that there is a trend occurring in which ATR is expressed in more normal tissues 
than tumor tissues. 
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ATR 
1 2 3 4 5 
GAPDH 
Lane 1 - MDA -MB -231 (12hrE2) 
Lane 2 - MDA -MB -231 (2hr E2) 
Lane 3 - MDA -MB .231 (No E2) 
Lane 4 _ MCF .7 (No E2) 
Lane 5 - 231 a (No E2) 
Figure 17. E2 regulation of ATR. RT-PCR analysis confirmed the regulation of ATR 
by E2 with time course treatment of MDA-MB-231 cells. Untreated samples of MCF-7 
and 231a cells were assayed for expression of ATR. GAPDH was used as an internal 
control. (PCR courtesy of collaboration efforts with Dr. Lisa Flowers’s laboratory, 
Emory University School of Medicine.) 
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Figure 18. Expression of ATR in breast tissues. RT-PCR analysis was performed 
using normal (N) and tumor (T) breast tissues to determine ATR expression. (A) 
Samples N4, T4, T5, T26 are ER+ and T14 is ER-. (B) There are 8 tissues (ION, 14T, 
22N, 24N, 26T, 42N, 47N, 66T) that are ER+ and 5 tissues (4N, 4T, 5T, 29T, 67T) that 
are ER-. GAPDEI was used as an internal eontrol. (PCR (A) courtesy of collaboration 
efforts with Dr. Lisa Flowers’s laboratory, Emory University School of Medicine.) 
Several other breast cancer cell lines were screened for the expression of ATR. 
The results are shown in Figure 19. ATR was expressed in all cell lines except the 
ERa/ERp negative MDA-MB-435 cell line. The BT 549 breast cancer cell line is also 
ERa/ERp negative, but expressed a detectable level of ATR. Therefore, the presence or 
absence of ERa and ERp is not associated with ATR expression. 
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ATR GAPDH 
Lane 1 & 9- 1 OObp marker 
Lane 2- MCF-7 
Lane 3- MDA-MB-231 
Lane 4- Neo 6 
Lane 5- 231 a 
Lane 6- MDA-MB-435 
Lane 7- MDA-MB-468 
Lane 8- BT 549 
Figure 19. ATR expression in various breast cancer cell lines. RT-PCR analysis was 
used to detect the expression of ATR in other breast cancer cell lines. GAPDH was used 
as an internal control to confirm approximately equal templates in all samples. 
CHAPTER 5 
DISCUSSION 
Estrogen has an essential role in the development of various tissues and in the 
maintenance of numerous physiological processes. However, it is also well known that 
estrogen plays a critical role in the etiology and progression of human breast and 
gynecological cancers. It was the purpose of this study to determine the effects of 
estrogen on gene expression of breast cancer cells independent of ERa. 
Gene expression profiles from ERa negative and positive breast cancer cells were 
created and examined following E2 treatment. The breast cancer cell lines utilized in 
these experiments were MDA-MB-231 and 231a. The MDA-MB-231 cell line is referred 
to in the literature as being ER-negative because it does not express ERa, but the results 
provided in this study show that detectable levels of ERp are expressed (Figure 5). 
Expression of ERp and its regulation by E2 have been analyzed in MDA-MB-231 and 
other ERp positive breast cancer cells (Vladusic, E. et al. 2000; Liu, S. et al. 2002). The 
231 a cells were created by stably transfecting ERa into MDA-MB-231 cells. The 
transfection was successful because the cells expressed ERa (Figure 5). MCF-7 breast 
cancer cell line was used as a control because it endogenously expresses ERa and ERp 
(Liu, S. et al. 2002; Cunliffe, H. et al. 2003). Figure 5 shows faint expression of ERp in 
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MCF-7 cells. This could be due to an error in the pipetting of primers or template. 
The Neo 6 cell line was created by transfecting the empty pcDNA3 expression 
vector into the MDA-MB-231 cell line. Success of transfection was determined by 
screening for the neomycin (NEO) resistant gene, which is incorporated into the vector 
for selection of stable transfectant cell lines (Figure 4). Neo 6 served as the control cell 
line for the transfectant cell line, 231a. 
The ability of E2 to induce cell proliferation has always been an aspect of interest 
in E2 studies. It has been well documented that E2 induced cell proliferation of breast 
cancer cells is relative to the expression of the ERs (Pike, M. et al. 1993). This is in part 
due to the fact that many of the growth promoting characteristics of estrogen are 
mediated through its ability to bind the ERs, a and p. In this study, the effects of E2 on 
the growth of cell lines MDA-MB-231,231a and Neo 6 were investigated. In the ERa 
negative MDA-MB-231 cell line, cell growth was slightly increased with E2 treatment 
after 48 hrs (Figure 6). This effect could be due to the declining levels of E2 over time, 
which allowed the cells to rebound and re-establish normal growth rate. Overall, E2 did 
not affect cell proliferation of MDA-MB-231 cells as previously determined by other 
studies (Levenson, A. and Jordan, V. 1994). E2 had a similar effect on the ERa 
transfected cell line 231a, but the growth rate was much higher (Figure 7). The cell 
density doubled every 24 hrs in both control and E2 treated samples, but after 72 hrs the 
rate increased four times in E2 treated cells. Previous studies by Lazennec et al. (2001) 
and Jiang et al. (1992) have documented that E2 causes growth inhibition in cells stably 
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expressing exogenous ERa. There was no inhibitory effect observed in this study. This 
could be an effect of clonality, in which the exogenous ERa is unable to take on the role 
of dominant mediator in the presence of endogenous ERP in our cloned cell line. Studies 
by Cheng and Malayer (1999) have shown that ERa had no ability to repress or inhibit 
cell proliferation in the presence of E2; therefore, illustrating that our data is not the first 
time this has been observed. In Neo 6, there was a substantial decrease in cell 
proliferation of E2 treated cells as well as in the control cells (Figure 8). It appears that 
the cells are dying daily instead of exhibiting a normal rate of growth as seen in the 
previous growth curves. This may be due to another clonal effect resulting from the 
transfection of the empty vector into the parental cell line, MDA-MB-231. Another 
aspect to consider is the method utilized to determine cell viability as referenced in the 
Materials and Methods. The cells are rinsed with dEEO to remove the crystal violet blue 
stain. During this process, viable cells may have been washed off causing the appearance 
of decreased cell proliferation. We have witnessed this before in the laboratory while 
attempting to determine the effects of E2 on cell proliferation of MCF-7 cells. Taken 
together, our results further support the past findings by other investigators that MDA- 
MB-23 1 cells are non-responsive to estrogen induced proliferation. Furthermore, these 
results imply that the presence of ERp does not play a role in proliferation. This 
probably occurs as a result of ERp having weaker transcriptional activity in response to 
E2 compared to ERa (Pettersson, K. et al. 2000). 
Microarray technology permits the transcriptional analysis of a large number of 
genes and gene products simultaneously. Using this technology in the identification of 
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E2 regulated genes in breast cancer cells is an essential step toward understanding the 
molecular mechanisms of E2 action. In this study the goal was to identify genes whose 
expression was regulated by E2 treatment in ERa negative and positive breast cancer cell 
lines. GeneChip® expression analysis (Affymetrix, Santa Clara, CA) was utilized to 
study gene expression profiles after E2 activation in MDA-MB-231 and 231a breast 
cancer cell lines. The results, taken together, illustrated that treatment with E2 altered the 
expression of a variety of genes; thereby, providing a comprehensive view of the changes 
induced by E2 on the transcriptional program of human E2-responsive/unresponsive 
cells. Ultimately, these findings could possibly identify genes that have the potential to 
serve as diagnostic/prognostic tools for the monitoring of breast cancer. 
Data analyses identified several genes that encode for protein kinases that act in 
DNA recombination, pre-mRNA splicing and signal transduction. There were also genes 
identified that participated in a variety of biological processes including cell growth, 
differentiation, pathogenesis, and tumor suppression. These genes can be found in Tables 
2-7. A number of genes known to be E2 regulated were found. They include BRCA1- 
associated protein 2 (BRAP2), vascular endothelial growth factor (VEGF), insulin-like 
growth factor binding protein (IGFB) and human estrogen receptor-related alpha 
(hERRa) (Frasor, J. et al. 2003). These findings help validate our data and imply that the 
ERa negative MDA-MB-231 cell line responds to E2 by mediating activation through 
alternative pathways. These alternative pathways may include ligand-independent 
receptor activation, non-nuclear action through cell-surface receptors or oxidative stress- 
mediated activation. The ER can be activated independently of E2 by growth factors that 
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increase the activity of protein kinases that phosphorylate different sites on the receptor. 
Phosphorylation occurs predominantly at specific serine or tyrosine residues and is 
catalyzed by enzymes such as receptor tyrosine kinases and mitogen-activated protein 
kinases (Gruber, C. et al. 2002). In the case of the non-nuclear E2 signaling pathway, the 
rapid events result from direct estrogenic action on cell membranes and are mediated by 
cell-surface forms of ER. Although these receptors remain mostly uncharacterized, they 
are thought to resemble their intracellular counterparts (Watson, C. et al. 1999). This 
activity is linked to the mitogen-activated protein kinase signaling cascade (Kato, S. et al. 
1995; Santen, R. et al. 2002; Zhang, Z. et al. 2002). The genotoxic activity of E2 is 
mediated by the tissue-specific conversion to catechol estrogen (CE) metabolites with 
subsequent formation of reactive oxygen species (ROS) and unstable CE intermediates 
(Yager, J. and Liehr, J. 1996; Yager, J. 2000; Liehr, J. 1999; Mobley, J. and 
Brueggemeier, R. 2004). This process fonns free radicals and allows the intermediates to 
bond covalently to DNA, which validates estrogen’s genotoxic activity. 
Further inspection of the microarray data was performed with GeneSpring 6.0 
software for gene expression data analysis. It allowed the data of two or more given 
samples to be viewed in order to determine the similarities and differences between gene 
expression profiles. Scatterplots were created from MDA-MB-231 and 231a samples 
(Figures 9-12). These images enabled the observation of the pattern of gene expression 
in E2 treated and untreated samples. It was interesting in this study to find that E2 caused 
a greater number of genes to be induced in MDA-MB-231 cells and more repressed in 
58 
231 a cells. These findings are similar to those of Frasor et al. (2003), in which they 
identified that seventy percent of the genes regulated by E2 in MCF-7 cells 
were down-regulated. It suggested that some of the estrogen-induced down-regulation of 
genes could be due to the squelching/sequestering of shared transcriptional coactivators 
that might be necessary for maintaining basal gene expression (McKay, L. and 
Cidlowski, J. 1999; Harnish, D. et al. 2000; Speir, E. et al. 2000). 
The key observation illustrated in the scatterplots is reinforced by the Venn 
diagrams (Figures 13 and 14). It is apparent that there are changes in gene expression 
attributable, not only to treatment, but also to the presence of ERa. The introduction of 
ERa into the MDA-MB-231 cells caused more genes to be repressed when exposed to E2 
than that seen in the wild type cell line. This observation is illustrated further by Tables 
8-10. These findings imply that the presence of ERa helps regulate gene expression and 
assists in confirming that an alternative mechanism for E2 activation may be the reason 
for the gene expression profile exhibited by MDA-MB-231 cells. 
There is an inferred or known function for the proteins that E2 regulated genes 
encode. Therefore, it was important to sort the genes by functional categories. The 
number of genes regulated by E2 in each category is illustrated in Figures 15 and 16. 
These figures further illustrate the difference in the number of genes regulated by E2 
between MDA-MB-231 and 231 a cell lines. This phenomenon could be due to several 
reasons. The first issue is that of aneuploidy; whenever foreign cDNA is introduced into 
an environment that does not express it endogenously there will be changes in 
chromosome number among the batch of cloned cells. These changes can cause 
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differences that affect the natural occurrences of the parental cell line. Secondly, 
endogenous genes may become down-regulated or deactivated with the introduction of 
exogenous cDNA (Vladusic, E. et al. 2000; Liu, S. et al. 2002; MacGregor-Shafer, J. et 
al. 2001). Previous works performed in the laboratory of V. Craig Jordan have 
successfully transfected ERa into MDA-MB-231 cells. Prior to transfection, the MDA- 
MB-231 cells were cloned and a clone (10A) was selected for transfection studies (Jiang, 
S.-Y. and Jordan, V.C. 1992). This clone is no longer representative of the wild type 
MDA-MB-231 cell line because it no longer expresses levels of ER(3 (Tonetti, D. et al. 
2003). Even though a homogeneous population of cells was created, it changed the 
phenotype of the parental cells; therefore, compromising any comparisons made between 
the newly created ERa-positive cell line and the ERa-negative cell line. 
An up-regulated cell cycle related gene that was first identified in the preliminary 
data analysis for 12 hr E2 treated MDA-MB-231 samples was found again by 
GeneSpring 6.0 analysis of 2 hr and 12 hr E2 treated MDA-MB-231 samples. ATR, 
ataxia telangiectasia mutated Rad3-related, belongs to the PI3K-related kinase 
(phosphatidylinositol 3-kinase) family (Cimprich, K. et al. 1996). It has a molecular 
mass of 301 kDa and functions in signaling the presence of DNA damage, activating cell 
cycle checkpoints, and repairing DNA. It has also been shown to phosphorylate 
checkpoint kinase 1, 2 (CHK 1,2), p53 and breast cancer 1 (BRCA1) (Chen, J. 2000; 
Bradbury, J. and Jackson, S. 2003). An important effect of these phosphorylation events 
is the control of cell cycle checkpoints. They ensure that the cell efficiently repairs the 
DNA damage before DNA replication or cell division occurs. 
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RT-PCR experiments were performed to confirm that the up-regulation of ATR 
by microarray experiments was truly estrogen-regulated (Figure 17). The difference in 
ATR expression was evident in untreated MDA-MB-231 cells compared to E2 treated 
MDA-MB-231 cells; thereby, validating that E2 induces ATR expression in MDA-MB- 
231 cells. Our identification of ATR as an E2 responsive gene is the first time this has 
been shown to date. RT-PCR analysis was performed using nonnal and tumor breast 
tissue samples, acquired through collaboration with Dr. Lisa Flowers at Emory 
University School of Medicine, to screen for ATR expression (Figure 18). ATR was 
expressed in tumor breast tissue samples, but not in the one normal breast tissue sample 
assayed (Figure 18A). These results imply that ATR has a role in breast cancer tumors, 
but an efficient number of nonnal and tumor breast tissue samples should be examined in 
order to validate this implication. We screened more breast tissue samples for ATR 
expression and noticed a trend occurring that implies that ATR is expressed in more 
nonnal tissues than in tumor tissues (Figure 18B). This suggests that ATR is adequately 
con-ecting the DNA damage that may occur in normal breast tissue. Once again, a larger 
number of breast tissue samples should be analyzed in order to statistically validate this 
implication. The expression of ATR was found in various breast cancer cell lines (Figure 
19) of different ER status; thereby, suggesting that ER status, in itself, does not determine 
expression levels of ATR. 
Disruption of the mechanisms that regulate cell cycle checkpoints, DNA repair, 
and apoptosis results in genomic instability and the development of cancer. ATR is one 
of the central players in checkpoint activation in response to DNA damage, making its 
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role pivotal in tumor suppression (Motoyama, N. and Naka, K. 2004). The identification 
of ATR as an E2 induced gene in MDA-MB-231 breast cancer cells providesimplications 
for its use in cancer therapy. Currently, there are studies being conducted that emphasize 
checkpoint kinases and their potential as cancer drug targets (Zhou, B. et al. 2003). 
Studying the signaling events that occur when ATR responds to DNA damage would 
identify the proteins most commonly responsible for inadequate DNA repair and tumor 
suppression. Therapeutic drugs could then be designed to target those specific proteins in 
order to suppress genomic instability, which is an important cause of tumorigenesis. 
Investigations by Yamane et al. (2004) have indicated that the ATR-Chkl pathway is 
involved in G2/M checkpoint response to DNA mismatches. This is important because 
DNA mismatch repair deficiency in cancers is associated with resistance to a myriad of 
clinically active chemotherapy drugs, thereby, providing insight into the reason many 
ERa negative breast tumors develop drug resistance. If the mechanism(s) responsible for 
preventing DNA mismatch repair is detennined, it could lead to the development of drugs 
that promote cancer treatment instead of enabling cancers to exhibit resistance to 
treatment. 
ATR expression results as a response to DNA damage (Tibbetts, R. et al. 2000; 
Zhou, B. and Elledge, S. 2000). The fonn of DNA damage must be specific, such as 
bulky lesions or stalled replications (O’Connell, M. et al. 2000; Khanna, K. et al. 2001; 
Shiloh, Y. 2001; Foray, N. et al. 2003). As seen in this study, E2 induces ATR 
expression in breast cancer cells through ER independent mechanisms. This leads to the 
62 
assumption that E2 is causing additional DNA damage, perhaps through an oxidative 
stress-mediated pathway. 
There are many reports that establish a link between estrogen-induced breast 
cancer and oxidative stress (Cavalieri, E., et al. 2000; Yager, J. 2000, Yager, J. et al. 
1996; Chen, Y. et al. 2000; Jefcoate, C. et al. 2000). A variety of estrogens are capable 
of acting as complete carcinogens through a mechanism that involves oxidative stress in 
the kidney, liver, and breast tissues of various rodent models (Mobley, J. and 
Brueggemeier, R. 2004; Elan, X. and Liehr, J. 1994). Therefore, the possibility exists that 
E2 treatment of MDA-MB-231 cells can cause the formation of reactive oxygen species 
(ROS), which initiate DNA damage that activate ATR. This phenomenon can be studied 
by treating MDA-MB-231 with E2, while measuring the changes in antioxidant status 
and sensitivity to DNA damage by peroxide. Estrogen-mediated oxidative DNA damage 
in mammary gland epithelia has been found to induce 8-oxo-2’-deoxyguanosine, thereby, 
suggesting a role for oxidative stress in the initiation and/or progression of breast 
neoplasia (Tagesson, S. et al. 1995; Wani, G. et al. 1998; Mobley, J. and Brueggemeier, 
R. 2004). It has been reported that physiologic concentrations of E2 can cause a decrease 
in catalase activity followed by an increase in glutathione peroxidase (GPx) activity in 
cultured normal human breast epithelial cells (Dabrosin, C. et al. 1998). There has also 
been reported changes in the antioxidant profile of breast cancer patients; including 
decreased catalase activity, decreased glutathione levels in sera, and changes in 
superoxide dismutase, GPx and glucose-6-phosphate dehydrogenase activities in tissues 
(Afrasyap, L. et al. 1998; Li, J. et al. 1998). These observations suggest that oxidative 
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stress induced DNA damage can occur from E2 exposure. This can be addressed by a 
series of experiments; including measuring estrogen-induced changes sensitive to 
peroxide-induced DNA damage, peroxide metabolism, total glutathione levels and 
enzyme activity assays (for example catalase and GPx activities) and western analysis to 
confirm enzyme studies. 
The expression of thousands of genes can now be determined simultaneously 
using microarray analysis. This study presented analysis of the observed patterns of gene 
expression in MDA-MB-231 and 231 a breast cancer cells untreated and treated for 2 and 
12 hrs with E2. There have been several studies of gene expression analysis of breast 
cancer cells treated with estrogens and selective estrogen receptor modulators relative to 
the activation of ERa, producing profiles of responsive genes. Even though these studies 
are valuable, there are only a few studies that address the need for developing catalogues 
of E2 responsive genes expressed in an ERa negative system. The data address this issue 
and provide a number of additional opportunities for future studies. Many of the 
regulated genes, including some very responsive genes, are ESTs. Investigation of these 
genes is likely to identify biochemical pathways relevant to the growth and differentiation 
of breast cancer cells that are not ERa positive. The power of gene clustering to define 
both distinct and overlapping patterns of gene expression associated with E2 can be 
demonstrated when all experimental conditions are analyzed together. Hierarchical 
clustering of this data would identify genes relevant to breast cancer in hormone 
independent cells. These expression clusters would allow the identification of distinct 
biological pathways regulated by E2 and provide the basis for future mechanistic studies. 
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In this study, we were able to identify genes regulated by E2 independent of the ERs in 
breast cancer cells. We also showed that the presence and/or absence of ERa affect the 
expression pattern of genes regulated by E2. A novel E2 regulated gene (ATR) 
associated with the cell cycle was identified and helped elucidate a possible alternative 
pathway for E2 activation. Ultimately, this study helps to provide a better understanding 
of estrogen’s influences on breast cancer and offers improved therapeutics for individuals 
with breast tumors that are unresponsive to hormone therapy and those that develop 
hormonal drug resistance. 
CHAPTER 6 
CONCLUSION 
The purpose of this project was to identify genes that were regulated by estrogen 
in an ERa-negative and positive breast cancer cell line. Differential microarray 
technology was utilized to study gene expression profiles after estrogen activation in 
MDA-MB-231 and 231 a human breast cancer cells. The results identified a diversity of 
genes whose expression was altered by estrogen. There were known estrogen-responsive 
genes that were expressed. These included VEGF, IGFB, BRCA2 and hERRa. In 
addition, a cell cycle associated gene was found to be up-regulated by estrogen that has 
not been shown to be estrogen-responsive to date. The gene is referred to as ATR and is 
a member of a family of P13K-related protein kinases. Preliminary results showed that it 
was up-regulated 6.8-fold in 12 hr estrogen treated cells. RT-PCR data confirmed that 
ATR was truly estrogen induced. Our data suggest ATR expression may not be 
associated with expression of ERs in breast cancer cell lines and it may occur more often 
in normal breast tissue than tumor breast tissue. Based on these results, we concluded 
that the induction of ATR expression by estrogen was mediated through non-ER 
mechanisms. 
In conclusion, this study has addressed the need for developing catalogues or 
profiles of genes regulated by E2 in an ERa-negative system, indicating that there are 
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non-ERa mechanisms mediating E2 activation. These findings will provide 
insight for effective treatment of breast cancers that are unresponsive to hormonal 
therapy, as well as those that develop drug resistance. The identification of estrogen- 
regulated genes in breast cancer cells is an essential step toward understanding the 
molecular mechanisms of estrogen action. 
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